STIO Life Science

www.stiolifescience.com

The Company STIO – LIFE SCIENCE (SLS) is a private Joint Stock Company that was established in 2016 as the First Egyptian Company dedicated to providing “Infection Prevention & Control-IPC” aiming “TO ACHIEVE HEALTH FOR ALL”. Shareholders structure STIO is a family-owned company with an Authorized Capital of EGP 50Million and Paid-in Capital EGP 15Million. STIO will focus on infection prevention and control (IPC). IPC is a practical proven set of organizational and technical approaches and measures to prevent the spread of avoidable infections and antimicrobial resistance (AMR) within both community and health care settings. As of January 2020, STIO has 7 products registered under its name in 32 different volumes and 2 products under registration. Major product cost and expansion programs will be covered from retained earnings and depend mostly on self-financing. STIO will build a large network of infection control specialists, physicians with different specialties, hospitals of different types & different specialized agencies in the field of IPC e.g. MOH IPC department, WHO….etc. Future market expansion will be toward MENA Region COMESA countries and Francophone African to fill the market gap in the IPC area.

Read more

Reach decision makers at STIO Life Science

Lusha Magic

Free credit every month!

The Company STIO – LIFE SCIENCE (SLS) is a private Joint Stock Company that was established in 2016 as the First Egyptian Company dedicated to providing “Infection Prevention & Control-IPC” aiming “TO ACHIEVE HEALTH FOR ALL”. Shareholders structure STIO is a family-owned company with an Authorized Capital of EGP 50Million and Paid-in Capital EGP 15Million. STIO will focus on infection prevention and control (IPC). IPC is a practical proven set of organizational and technical approaches and measures to prevent the spread of avoidable infections and antimicrobial resistance (AMR) within both community and health care settings. As of January 2020, STIO has 7 products registered under its name in 32 different volumes and 2 products under registration. Major product cost and expansion programs will be covered from retained earnings and depend mostly on self-financing. STIO will build a large network of infection control specialists, physicians with different specialties, hospitals of different types & different specialized agencies in the field of IPC e.g. MOH IPC department, WHO….etc. Future market expansion will be toward MENA Region COMESA countries and Francophone African to fill the market gap in the IPC area.

Read more
icon

Country

icon

City (Headquarters)

Cairo

icon

Employees

11-50

icon

Founded

2016

icon

Social

  • icon

Employees statistics

View all employees

Potential Decision Makers

  • Deputy Chief Executive Officer

    Email ****** @****.com
    Phone (***) ****-****
  • Supply Chain Manager

    Email ****** @****.com
    Phone (***) ****-****

Reach decision makers at STIO Life Science

Free credits every month!

My account

Sign up now to uncover all the contact details